Key result
Tanshinone IIA pretreatment reduced myocardial infarct size and improved left ventricular ejection fraction after ischaemia/reperfusion injury in diabetic rats.
Why the study?
Does tanshinone IIA pretreatment reduce myocardial infarct size and improve cardiac function in diabetic rats subjected to ischemia/reperfusion injury?
RCT (n=80)
randomized
Does tanshinone IIA pretreatment reduce myocardial infarct size and improve cardiac function in diabetic rats subjected to ischemia/reperfusion injury?
Tanshinone IIA pretreatment reduces infarct size and improves cardiac function after ischemia/reperfusion injury in diabetic rats via the PI3K/Akt pathway.
Answers are grounded in this paper and cite their sources.
Extends tanshinone IIA cardioprotection data to diabetic animals; leaves open translation to human diabetic patients with ischaemia/reperfusion injury.
AIM: Diabetes Mellitus (DM) is widely acknowledged to increase the risk of cardiovascular death, which warrants the use of aggressive primary prevention strategies. The aim of the present study was to investigate the pretreatment effects of tanshinone IIA (TSN), a traditional Chinese medicine, on myocardial infarct size, apoptosis, inflammation and cardiac functional recovery in diabetic rats subjected to myocardial ischaemia/reperfusion (I/R). METHODS: Streptozocin (STZ) induced diabetic rats (n = 80) were randomized to receive TSN, TSN plus wortmannin [a phosphatidylinositol 3-kinase (PI3K) inhibitor] or saline. They were exposed to a 30-min ischaemia by ligation of the left coronary artery except for the sham group. Haemodynamics, infarct size and myocardial apoptosis were examined 3 h after reperfusion. The effects of TSN on Akt and NF-kappaB phosphorylation and the expression of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in cardiac tissues were examined. RESULTS: Our results revealed that TSN administration significantly reduced myocardial infarct size (0.252 +/- 0.038 vs. 0.327 +/- 0.027, p < 0.05), improved left ventricular ejection fraction (LVEF) (0.774 +/- 0.058 vs. 0.716 +/- 0.054, p < 0.05), decreased myocardial apoptotic death (0.114 +/- 0.026 vs. 0.191 +/- 0.023, p < 0.05) compared with I/R group. Western blot analysis showed that TSN treatment enhanced Akt phosphorylation and inhibited NF-kappaB phosphorylation in cardiac tissues. Moreover, pretreatment with wortmannin abolished the beneficial effects of TSN: a reduction of infarct size, a decrease in LVEF, inhibition of myocardial apoptosis and Akt phosphorylation, enhancement of NF-kappaB phosphorylation and an increase of cytokine production including TNF-alpha and IL-6 after I/R injury in diabetic rats. CONCLUSIONS: This study indicates that TSN pretreatment reduces infarct size and improves cardiac dysfunction after I/R injury in diabetic rats. This was accompanied with decreased cardiac apoptosis and inflammation. The possible mechanism responsible for the effects of TSN is associated with the PI3K/Akt-dependent pathway.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2009) conducted an RCT in Diabetes Mellitus with myocardial ischaemia/reperfusion injury (n=80). Tanshinone IIA (TSN) vs. saline was evaluated on myocardial infarct size (p=< 0.05). Tanshinone IIA pretreatment reduced myocardial infarct size and improved left ventricular ejection fraction after ischaemia/reperfusion injury in diabetic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: